Becher K F, Madersbacher S, Michel M C
Abteilung für Geriatrie und Frührehabilitation, Helios Hanseklinikum Stralsund GmbH, Stralsund, Deutschland.
Abteilung für Urologie, Kaiser Franz Josef Spital, Sigmund Freud Privatuniversität, Wien, Österreich.
Urologe A. 2019 Mar;58(3):248-253. doi: 10.1007/s00120-019-0871-z.
Based on new evidence, we discuss the risk of central nervous side effects, mainly reduced cognition/dementia and depressive symptoms during the use of drugs for the treatment of lower urinary symptoms suggestive of benign prostatic hyperplasia. Cognitive impairments during use of muscarinic antagonists are well documented and mechanistically well understood, but their occurrence differs quantitatively between members of this drug class. The occurrence of depressive symptoms while using 5α-reductase inhibitors only became known recently but has now been observed consistently in several studies and is mechanistically plausible; it appears to occur with similar incidence when using dutasteride and finasteride. A moderate increase in new diagnoses of dementia has recently been reported from a single study upon use of tamsulosin but not other α-adrenoceptor antagonists. The plausibility of a mechanistic cause-effect relationship is only moderate, and the association could be explained based on selection bias. Overall, physicians should be alert for the occurrence of central nervous side effects during the treatment of lower urinary tract symptoms.
基于新的证据,我们讨论了在使用治疗提示良性前列腺增生的下尿路症状的药物过程中出现中枢神经副作用的风险,主要是认知能力下降/痴呆和抑郁症状。使用毒蕈碱拮抗剂期间的认知障碍有充分的文献记载,其机制也得到了很好的理解,但在这类药物的不同成员中,其发生率在数量上有所不同。使用5α-还原酶抑制剂时出现抑郁症状只是最近才为人所知,但现在已在多项研究中得到一致观察,且在机制上是合理的;使用度他雄胺和非那雄胺时,其发生率似乎相似。最近有一项研究报告称,使用坦索罗辛后痴呆新诊断病例有适度增加,但使用其他α-肾上腺素能拮抗剂时未出现这种情况。机械性因果关系的合理性仅为中等,这种关联可能是基于选择偏倚来解释的。总体而言,医生在治疗下尿路症状时应警惕中枢神经副作用的发生。